JP2016503434A - ケモカイン−サイトカイン融合タンパク質およびその利用 - Google Patents
ケモカイン−サイトカイン融合タンパク質およびその利用 Download PDFInfo
- Publication number
- JP2016503434A JP2016503434A JP2015545618A JP2015545618A JP2016503434A JP 2016503434 A JP2016503434 A JP 2016503434A JP 2015545618 A JP2015545618 A JP 2015545618A JP 2015545618 A JP2015545618 A JP 2015545618A JP 2016503434 A JP2016503434 A JP 2016503434A
- Authority
- JP
- Japan
- Prior art keywords
- chemokine
- fusion protein
- polypeptide
- cytokine
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (16)
- 融合タンパク質であって、
ケモカインまたはその受容体結合ドメインであるケモカインポリペプチドと、
インターロイキン、TNF−スーパーファミリーサイトカイン、またはその受容体結合ドメインである、前記ケモカインポリペプチドに結合されたサイトカインポリペプチドと、
を含み、そのうち、前記ケモカインポリペプチドと前記サイトカインポリペプチドが共通標的細胞を有し、前記融合タンパク質が前記ケモカインポリペプチドと比較して向上されたケモカイン活性と、前記サイトカインポリペプチドと比較して向上されたサイトカイン活性を有することを特徴とする、融合タンパク質。 - 前記ケモカインポリペプチドと前記サイトカインポリペプチドが、ペプチドリンカーにより結合されることを特徴とする、請求項1に記載の融合タンパク質。
- 前記ケモカインが、CXCケモカイン、CCケモカイン、Cケモカイン、CX3Cケモカインから構成される群より選択されることを特徴とする、請求項1に記載の融合タンパク質。
- 前記ケモカインが、CXCケモカインであることを特徴とする、請求項3に記載の融合タンパク質。
- 前記ケモカインが、ストローマ細胞由来因子またはIL−8であることを特徴とする、請求項4に記載の融合タンパク質。
- 前記ケモカインポリペプチドが、SEQ ID NO:2、4、6、8、10、12、14、16、18、およびそのホモログとそのアナログから選択されたアミノ酸配列を有することを特徴とする、請求項1に記載の融合タンパク質。
- 前記サイトカインポリペプチドが、IL−2、CD40リガンドまたはその受容体結合ドメインであることを特徴とする、請求項1に記載の融合タンパク質。
- 前記サイトカインポリペプチドが、SEQ ID NO:20、22、24、26、28、30、32、34、36、38、およびそのホモログとそのアナログから選択されたアミノ酸配列を有することを特徴とする、請求項1に記載の融合タンパク質。
- SEQ ID NO:40、42、44、46、48から選択されたアミノ酸配列を有することを特徴とする、請求項1に記載の融合タンパク質。
- 請求項1乃至5のいずれかに記載の融合タンパク質をエンコードすることを特徴とする、単離された核酸分子。
- SEQ ID NO:1、3、5、7、9、11、13、15、17、およびそのホモログとそのアナログから選択される、ケモカインポリペプチドをエンコードするヌクレオチド配列を含むことを特徴とする、請求項10に記載の単離された核酸分子。
- SEQ ID NO:19、21、23、25、27、29、31、33、35、37、およびそのホモログとそのアナログから選択される、ケモカインポリペプチドをエンコードするヌクレオチド配列を含むことを特徴とする、請求項10に記載の単離された核酸分子。
- SEQ ID NO:39、41、43、45、47から選択された配列を有することを特徴とする、請求項10に記載の単離された核酸分子。
- 請求項10乃至13のいずれかに記載の核酸分子を含むことを特徴とする、発現ベクター。
- 請求項10乃至13のいずれかに記載の核酸分子を含むことを特徴とする、宿主細胞。
- 請求項14に記載の発現ベクターを含むことを特徴とする、宿主細胞。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/001629 WO2014085947A1 (zh) | 2012-12-05 | 2012-12-05 | 趋化素-细胞素融合蛋白和其应用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016503434A true JP2016503434A (ja) | 2016-02-04 |
JP2016503434A5 JP2016503434A5 (ja) | 2017-03-30 |
JP6174710B2 JP6174710B2 (ja) | 2017-08-02 |
Family
ID=50882722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015545618A Active JP6174710B2 (ja) | 2012-12-05 | 2012-12-05 | ケモカイン−サイトカイン融合タンパク質およびその利用 |
Country Status (7)
Country | Link |
---|---|
US (4) | US20150307577A1 (ja) |
EP (1) | EP2930189B1 (ja) |
JP (1) | JP6174710B2 (ja) |
CN (1) | CN104968686B (ja) |
AU (1) | AU2012396113B2 (ja) |
CA (1) | CA2893981C (ja) |
WO (1) | WO2014085947A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
WO2022225862A1 (en) * | 2021-04-19 | 2022-10-27 | Walking Fish Therapeutics | Methods of b cell expansion for use in cell therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001040311A1 (fr) * | 1999-11-30 | 2001-06-07 | Shionogi & Co., Ltd. | Proteine fusionnee de chimiokine slc-il2 |
WO2003035105A2 (en) * | 2001-10-23 | 2003-05-01 | Centre For Translational Research In Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU778611B2 (en) * | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
CA2322687A1 (en) * | 1999-10-29 | 2001-04-29 | Regents Of The University Of California | Compositions containing c-terminal polypeptides of angiogenic chemokines and methods of use |
US20050287118A1 (en) * | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
CN101445560A (zh) * | 2008-12-31 | 2009-06-03 | 河南省生物工程技术研究中心 | 一种畜禽用融合蛋白的制备方法 |
-
2012
- 2012-12-05 CA CA2893981A patent/CA2893981C/en active Active
- 2012-12-05 CN CN201280077622.3A patent/CN104968686B/zh active Active
- 2012-12-05 AU AU2012396113A patent/AU2012396113B2/en active Active
- 2012-12-05 JP JP2015545618A patent/JP6174710B2/ja active Active
- 2012-12-05 US US14/649,714 patent/US20150307577A1/en not_active Abandoned
- 2012-12-05 WO PCT/CN2012/001629 patent/WO2014085947A1/zh active Application Filing
- 2012-12-05 EP EP12889511.7A patent/EP2930189B1/en active Active
-
2017
- 2017-07-25 US US15/658,929 patent/US10336801B2/en active Active
-
2019
- 2019-05-17 US US16/415,143 patent/US20190270788A1/en not_active Abandoned
-
2023
- 2023-03-17 US US18/122,768 patent/US20230265150A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001040311A1 (fr) * | 1999-11-30 | 2001-06-07 | Shionogi & Co., Ltd. | Proteine fusionnee de chimiokine slc-il2 |
WO2003035105A2 (en) * | 2001-10-23 | 2003-05-01 | Centre For Translational Research In Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
Also Published As
Publication number | Publication date |
---|---|
US20230265150A1 (en) | 2023-08-24 |
EP2930189A1 (en) | 2015-10-14 |
CA2893981C (en) | 2021-11-16 |
JP6174710B2 (ja) | 2017-08-02 |
CA2893981A1 (en) | 2014-06-12 |
US10336801B2 (en) | 2019-07-02 |
EP2930189A4 (en) | 2016-06-08 |
US20190270788A1 (en) | 2019-09-05 |
EP2930189B1 (en) | 2020-04-29 |
US20170327554A1 (en) | 2017-11-16 |
CN104968686B (zh) | 2020-02-04 |
WO2014085947A1 (zh) | 2014-06-12 |
AU2012396113B2 (en) | 2017-03-30 |
AU2012396113A1 (en) | 2015-07-02 |
US20150307577A1 (en) | 2015-10-29 |
CN104968686A (zh) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230265150A1 (en) | A fusion proteon of stromal cell-derived factor-1 (sdf-1) and interleukin-2 (il-2) and applications thereof | |
Wang et al. | First in-depth analysis of the novel Th2-type cytokines in salmonid fish reveals distinct patterns of expression and modulation but overlapping bioactivities | |
Zou et al. | The function of fish cytokines | |
Wang et al. | Interleukin (IL)-2 is a key regulator of T helper 1 and T helper 2 cytokine expression in fish: functional characterization of two divergent IL2 paralogs in salmonids | |
Yin et al. | Carp interleukin-1beta in the role of an immuno-adjuvant | |
WO2005090400A1 (en) | Immunosuppressive cytokine | |
Sanchez et al. | Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8 | |
Karan et al. | Structural and functional characterization of recombinant interleukin-10 from Indian major carp Labeo rohita | |
Chen et al. | Enhancement of immune response of piglets to PCV-2 vaccine by porcine IL-2 and fusion IL-4/6 gene entrapped in chitosan nanoparticles | |
Rahman et al. | Prospects and challenges of using chicken cytokines in disease prevention | |
CN111018994A (zh) | 一种vzv病毒亚单元融合抗原 | |
WO2024066416A1 (zh) | Cxcl-bpi融合蛋白及其用途 | |
CN112662695A (zh) | 一种细菌生物膜囊泡(bbv)作为疫苗载体的构建方法和应用 | |
TWI487713B (zh) | 趨化素-細胞素融合蛋白和其應用 | |
Abraha | Review on the role and biology of cytokines in adaptive and innate immune system | |
Ward et al. | E. coli expression and purification of human and cynomolgus IL-15 | |
Orishchenko et al. | Effect of human double-stranded DNA preparation on the production of cytokines by dendritic cells and peripheral blood cells from relatively healthy donors | |
Wei et al. | Cloning and characterization of goose interleukin-17A cDNA | |
Peymanfar et al. | Production and simple purification of recombinant human granulocyte colonystimulating factor using the inteintag in Escherichia Coli | |
CN104258376B (zh) | 可溶性i型鸭肝炎病毒3d蛋白在制备i型鸭病毒性肝炎疫苗的免疫增强剂中的应用 | |
WO2014172805A1 (zh) | 具有增进的细胞素活性的组合物和其应用 | |
Yu et al. | Actin depolymerizing factor-based nanomaterials: A novel strategy to enhance E. mitis-specific immunity | |
Soontara et al. | Adjuvant Effects of a CC Chemokine for Enhancing the Efficacy of an Inactivated Streptococcus agalactiae Vaccine in Nile Tilapia (Oreochromis niloticus) | |
TW201441250A (zh) | 具有增進的細胞素活性的組合物和其應用 | |
Huang et al. | Study on the Immunogenicity of Three Recombinant Lactic Acid Bacteria Expressing ASFV p14. 5 Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161129 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170613 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170706 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6174710 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |